74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
BioMerieux
Closed
Sector Healthcare
112.9 -1.22
Overview
Share price change
24h
Min
112.6
Max
112.9
Income | 215M |
|---|---|
Sales | -1.1B 785M |
P/E Sector Avg | 32.853 73.394 |
Dividend yield | 0.74 |
Profit margin | 11.32 |
Employees | 13,409 |
EBITDA | -247M 161M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +14.84 upside |
Dividend yield Sector Avg | 0.74% 3.09% |
|---|---|
Next Earnings | 7 Mar 2025 |
Market Cap | 13B |
|---|---|
Previous open | 114.12 |
Previous close | 112.9 |
News Sentiment
By Acuity
29%
71%
67 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
BioMerieux Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
BioMerieux Forecast
Price Target
By TipRanks
14.84% upside
12 Months Forecast
Average 129.2 EUR 14.84%
High 132 EUR
Low 123 EUR
Based on 5 Wall Street analysts offering 12 month price targets forBioMerieux - Dist in the last 3 months.
Sentiment
By Acuity
67 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About BioMerieux
bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VITEK 2, an automated Identification and antimicrobial susceptibility testing (AST) system; API RANGE standardized ID strips; VITEK REVEAL Rapid AST system; ETEST Gradient method on culture media; BIOMERIEUX EPISEQ CS whole genome sequencing solution for epidemiologic monitoring; and VIDASB·R·A·H·M·S PCTTM, a specific marker of severe bacterial infections/sepsis. It also provides Biomérieux vision suite, a software that provides actionable information to support diagnosis and clinical decision making; culture media and associated instruments; ARGENE Monoplex PCR tests; NUCLISENS ranges, a product for automation of the molecular biology laboratory and extraction; EMAG system For DNA and RNA extraction; ESTREAM, an automated preparation station for samples to process PCR tests; GENE-UP and VERIFLOW ranges for detection of microorganisms for the food industry. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.
